Table 8

Individual ambulatory care expenditures for patients with type T2DM and declining renal function in 2010 (€)
Pharmacy Consultation (GP/specialist) Nursing care Total ambulatory care costs
Monotherapy (N = 411) m (σ) 1,798 (2,433) 307 (252) 143 (683) 4,226 (5,369)
Increase rate vs NRF 56% 20% 0% 40%
Double therapy (N = 267) m (σ) 1,893 (3,908) 301 (171) 210 (963) 4,159 (5,268)
Cost ratio vs mono (%) 1.094* 0.978 0.736 0.959
Increase rate vs NRF 34% 21% 38% 26%
Triple therapy (N = 78) m (σ) 2,141 (3,056) 305 (152) 99 (504) 4,032 (4,329)
Cost ratio vs mono (%) 1.262 *** 1.029 0.903 1.031
Increase rate vs NRF 19% 17% 5% 12%
Insulin therapy (N = 267) m (σ) 3,889 (5,363) 422 (340) 2,161 (3,638) 11,344 (11,185)
Cost ratio vs mono (%) 2.020 *** 1.230 *** 10.236 *** 2.223***
Increase rate vs NRF 47% 28% 36% 53%

* 0.01 < p < 0.05; ** 0.001 < p < 0.01; *** p < 0.001.

Guelfucci et al.

Guelfucci et al. BMC Endocrine Disorders 2013 13:15   doi:10.1186/1472-6823-13-15

Open Data